For cytomix treatment, human recombinant TNFα (R&D Systems), IFNγ (R&D systems), and IL‑1β (PeproTech) were dissolved in organoid media and added to the organoid wells overnight for 16 h, after which organoids were washed twice with Advanced DMEM/F12 and then replaced with organoid media.
